Drug intelligence / Profile preview

MZeDT3

Development stage
Preclinical
Lead developer
University of Copenhagen
Modality
PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration
Intravenous, Intraperitoneal
01

Overview

MZeDT3 is a first-in-class, highly selective Proteolysis Targeting Chimera (PROTAC) designed to induce the degradation of ZAKα (MAP3K20), a key kinase involved in the ribotoxic stress response (RSR). ZAKα acts as a sensor for stalled ribosomes, triggering downstream signaling pathways like p38 and JNK MAP kinases in response to various stressors, including UV radiation and ribotoxic toxins. MZeDT3 consists of a ZAKα-binding ligand (based on the scaffold of the kinase inhibitor MZe786) linked to a von Hippel-Lindau (VHL) E3 ligase recruiter. By depleting ZAKα protein levels, MZeDT3 effectively blocks the RSR, providing a powerful tool for studying the biological roles of ZAKα and potentially serving as a lead compound for treating diseases driven by aberrant RSR signaling, such as UV-induced skin damage or metabolic stress.

Other names
ZAKα PROTAC
02

Targets

PK (Pyruvate kinase)VHL (Von Hippel–Lindau tumor suppressor protein)

Beyond the preview

Go deeper on MZeDT3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MZeDT3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call